Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Metformin effects revisited.

Andújar-Plata P, Pi-Sunyer X, Laferrère B.

Diabetes Res Clin Pract. 2012 Jan;95(1):1-9. doi: 10.1016/j.diabres.2011.09.022. Epub 2011 Oct 14. Review.

3.

Safety and efficacy of metformin in patients with type 2 diabetes mellitus and chronic hepatitis C.

Harris K, Smith L.

Ann Pharmacother. 2013 Oct;47(10):1348-52. doi: 10.1177/1060028013503108. Review.

PMID:
24259699
4.

Metformin hydrochloride in the treatment of type 2 diabetes mellitus: a clinical review with a focus on dual therapy.

Setter SM, Iltz JL, Thams J, Campbell RK.

Clin Ther. 2003 Dec;25(12):2991-3026. Review.

PMID:
14749143
5.

[Metformin - mechanisms of action and use for the treatment of type 2 diabetes mellitus].

Grzybowska M, Bober J, Olszewska M.

Postepy Hig Med Dosw (Online). 2011 May 6;65:277-85. Review. Polish.

6.

Metformin in cancer treatment and prevention.

Morales DR, Morris AD.

Annu Rev Med. 2015;66:17-29. doi: 10.1146/annurev-med-062613-093128. Epub 2014 Nov 6. Review.

PMID:
25386929
7.

A comparison of the effects of thiazolidinediones and metformin on metabolic control in patients with type 2 diabetes mellitus.

Seufert J, Lübben G, Dietrich K, Bates PC.

Clin Ther. 2004 Jun;26(6):805-18. Review.

PMID:
15262452
8.

Metformin monotherapy for type 2 diabetes mellitus.

Saenz A, Fernandez-Esteban I, Mataix A, Ausejo M, Roque M, Moher D.

Cochrane Database Syst Rev. 2005 Jul 20;(3):CD002966. Review. Update in: Cochrane Database Syst Rev. 2015;9:CD002966.

PMID:
16034881
9.

Metformin action on AMP-activated protein kinase: a translational research approach to understanding a potential new therapeutic target.

Boyle JG, Salt IP, McKay GA.

Diabet Med. 2010 Oct;27(10):1097-106. doi: 10.1111/j.1464-5491.2010.03098.x. Review.

PMID:
20854376
10.

The cardiovascular effects of metformin: further reasons to consider an old drug as a cornerstone in the therapy of type 2 diabetes mellitus.

Anfossi G, Russo I, Bonomo K, Trovati M.

Curr Vasc Pharmacol. 2010 May;8(3):327-37. Review.

PMID:
19485923
11.

Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.

Boland CL, Degeeter M, Nuzum DS, Tzefos M.

Ann Pharmacother. 2013 Apr;47(4):490-505. doi: 10.1345/aph.1R444. Epub 2013 Apr 2. Review.

PMID:
23548652
12.

New insights into the anti-diabetic actions of metformin: from the liver to the gut.

Wu T, Horowitz M, Rayner CK.

Expert Rev Gastroenterol Hepatol. 2017 Feb;11(2):157-166. doi: 10.1080/17474124.2017.1273769. Epub 2016 Dec 26. Review.

PMID:
27983877
13.

Metformin: from mechanisms of action to therapies.

Foretz M, Guigas B, Bertrand L, Pollak M, Viollet B.

Cell Metab. 2014 Dec 2;20(6):953-66. doi: 10.1016/j.cmet.2014.09.018. Epub 2014 Oct 30. Review.

14.

Metformin and Inflammation: Its Potential Beyond Glucose-lowering Effect.

Saisho Y.

Endocr Metab Immune Disord Drug Targets. 2015;15(3):196-205. Review.

PMID:
25772174
15.

[Metformin and AMPK: an old drug and a new enzyme in the context of metabolic syndrome].

Santomauro Júnior AC, Ugolini MR, Santomauro AT, Souto RP.

Arq Bras Endocrinol Metabol. 2008 Feb;52(1):120-5. Review. Portuguese.

16.

Metformin for prevention of type 2 diabetes.

Hess AM, Sullivan DL.

Ann Pharmacother. 2004 Jul-Aug;38(7-8):1283-5. Epub 2004 May 18. Review.

PMID:
15150378
18.

Metformin: an antihyperglycemic agent for treatment of type II diabetes.

Melchior WR, Jaber LA.

Ann Pharmacother. 1996 Feb;30(2):158-64. Review.

PMID:
8835050
19.

The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus.

Charokopou M, McEwan P, Lister S, Callan L, Bergenheim K, Tolley K, Postema R, Townsend R, Roudaut M.

Diabet Med. 2015 Jul;32(7):890-8. doi: 10.1111/dme.12772. Epub 2015 Apr 30.

PMID:
25817050
20.

Supplemental Content

Support Center